Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘CART19’

San Diego – Monday at the 2016 Annual Meeting of the American Society of Hematology (#ASH16) is typically a day of multiple oral sessions in parallel.

This year it was a major challenge doing a mad dash between sessions as the meeting is now so big that in San Diego it’s being held, not only at the vast convention center, but is also using the meeting rooms of three nearby three hotels – it’s literally a mile walk to go from one end of the convention to the other, so you have to factor that time into your crazed schedule with multiple clashes.

On the positive side, there’s even courtesy pedicabs – cycle rickshaws (great idea & fun) – I caught one at 7am the other day to save my toes from at least one #blisterwalk…

Pedicab at ASH16 in San Diego

Following on from our ASH Highlights 2016 Part 1, this post answers critical BSB Reader questions that have come in thick and fast and require more than 140 characters on Twitter to answer.

Predictably, the majority of the first tranche of questions have been CAR T cell therapy related, so if you have a keen interest in this area, this is the post for you.  We tackle 5 critical questions and offer some insights.

Subscribers can login to read more or you can purchase access below via the blue box.

One of the fun aspects of the American Society of Hematology (ASH) conference last month was interviewing several thought leaders and CEOs about the latest developments that were emerging rapidly almost every single day.  Now, some medical meetings can be rather dreary if there’s no new or exciting data to pique the interest of the foot weary attendees, who tend to run on coffee and adrenalin for four days, but this ASH was rather different.

Looking at the program the first morning, I realised that I hadn’t felt so much anticipation since the 1999 meeting, when the phase I imatinib (Gleevec) data was presented in the plenary session by Brian Druker.  This time around there was a lot of buzz in so many areas from CLL and NHL to myeloma and ALL, it was pretty exciting to run from session to and see many packed rooms filled with an air of expectancy.  One evening, I hesitated at the top of an escalator and dithered over which of three very interesting sessions to dash to, as a bunch of researchers crashed into me all distracted by the exactly same dilemma!

If many of us could have made one request of the ASH organising committee it was clearly start offering a virtual meeting for all the oral sessions, something ASCO do incredibly well.

At ASH if you miss a presentation, it’s gone forever.

This is quite a pain if you really wanted to see the data from Agent X in CLL, Compound Y in CAR T cells and Drug Z in myeloma, as well as the one you actually attended.  All those sessions ran simultaneously.  It also means the sessions are still running at 7pm (yes, they were still packed even at that hour!) and many of us had an early start with 7am sessions or meetings.

The huge distances between rooms (#blisterruns), coupled with a stubborn insistence in putting almost all the oral sessions on Monday and Tuesday, together with long waits between interesting sessions over the weekend, makes for a very frazzled and disjointed schedule. Patience and stamina are the name of the game here.

Despite scattered logistics, the conference was actually a lot of fun. If I had to compile a top 10 of key abstracts I really liked in New Orleans then it would take a long time, simply because there was so much new data requiring much agonising over what to leave out.

Stephan GruppThat said, one interview I particularly enjoyed was with Dr Stephan Grupp, a pediatric hematologist who is the Director of Translational Research, Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia (CHOP).  By an odd quirk of the schedule, it seemed that he and I always seemed to be in the same sessions, although we actually spoke by phone afterwards, given the craziness in both our schedules.

There were two events in particular that were notable highlights:

  • A fascinating and well-thought out hour long seminar that Dr Grupp and Dr Elizabeth Shpall (MD Anderson) hosted on “Featured Topic: Chimeric Antigen Receptors (CAR): Driving Immunotherapy!” where they summarised the progress in this field in a lively, very fair minded and balanced fashion.
  • An oral presentation on the “Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL” [Abstr #4162]

The lunchtime seminar was simply outstanding and incredibly educational, with attendees jam packed into a tiny hall they could probably have filled three times over. It was worth the registration fee for this one event alone, it was that good. Definitely one of my top 10 highlights.

The refractory pALL study was my favourite data from the conference, though it was sadly not in the plenary. Many attendees present in New Orleans whom I spoke to, however, clearly thought it was very worthy of a such a slot. The approach and results were groundbreaking and impressive.

If you are interested in reading the interview with Dr Grupp and our insights on this area, please sign in or sign up in the box below to continue.

error: Content is protected !!